Menu Search
Equities

DURECT Corp

DRRX:NAQ

DURECT Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.919
  • Today's Change0.056 / 6.54%
  • Shares traded6.06k
  • 1 Year change+41.38%
  • Beta1.0421
Data delayed at least 15 minutes, as of Nov 22 2024 15:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for DURECT Corp have a median target of 6.75, with a high estimate of 8.50 and a low estimate of 5.00. The median estimate represents a 682.52% increase from the last price of 0.8626.
High885.4%8.50
Med682.5%6.75
Low479.6%5.00

Earnings history & estimates in USD

On Nov 13, 2024, DURECT Corp reported 3rd quarter 2024 losses of -0.14 per share. This result exceeded the -0.17 consensus loss of the 3 analysts covering the company and was the same as last year's 3rd quarter results.
The next earnings announcement is expected on Mar 19, 2025.
Average growth rate-21.52%
DURECT Corp reported annual 2023 losses of -1.20 per share on Mar 27, 2024.
Average growth rate+12.85%
More ▼

Revenue history & estimates in USD

DURECT Corporation had 3rd quarter 2024 revenues of 1.93m. This missed the 1.98m consensus estimate of the 3 analysts following the company. This was 6.18% below the prior year's 3rd quarter results.
Average growth rate+7.27%
DURECT Corporation had revenues for the full year 2023 of 8.55m. This was 55.67% below the prior year's results.
Average growth rate-17.36%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.